Ra Med Electrophysiology Division Announces New Publication of Clinical Data

Rhea-AI Summary

Ra Medical Systems (NYSE American: RMED) announced significant findings regarding its product VIVO, a non-invasive localization system, following a recent publication from the Royal Brompton Hospital. The study shows that utilizing VIVO reduces ventricular ablation mapping time by nearly 30%, contributing to shorter overall procedure times and enhanced patient safety. Importantly, the data suggests that patients previously unable to undergo ablation can now have successful procedures, expanding treatment options for those with rare ventricular arrhythmias. With close to 1,000 procedures performed, VIVO is gaining traction, and its clinical acceptance is anticipated to grow.

Positive

• VIVO reduces ventricular ablation mapping time by nearly 30%, leading to shorter procedure times.
• Patients previously unable to undergo ablation now have successful procedure options.
• Close to 1,000 procedures have been performed using VIVO, indicating growing clinical acceptance.

Negative

• None.

New Study Confirms Advantages of Using VIVO for Pre-Procedure Ventricular Ablation Planning

FORT MILL, SC / ACCESSWIRE / March 8, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) announced today that its wholly owned subsidiary, Catheter Precision, Inc., has had new clinical data published for its leading product VIVO (View Into Ventricular Onset), that confirms the perceived benefits of using VIVO in a ventricular ablation program.

VIVO is a non-invasive localization system that provides the physician with data about the patient's heart prior to a ventricular ablation. This data is then used by the physician to plan certain aspects of the procedure including where to look for the start of the arrhythmia (often the target for the ablation), which can be a time-consuming process.

The newest publication (https://www.sciencedirect.com/science/article/pii/S0022073623000250) by the Royal Brompton Hospital (London, UK) with lead author Professor Sabine Ernst, confirms that VIVO does reduce mapping time by almost 30%. A reduction in mapping time leads to a total reduction in procedure time, potentially increasing patient safety. In addition, this publication discusses that patients with previous ablations that were unable to be performed were now able to have successful ablation procedures improving treatment options for patients with infrequent ventricular arrhythmias.

"We have seen for some time that using VIVO would have many benefits," said David Jenkins, CEO. "It is great to have data that shows how pre-procedure planning with VIVO can provide benefits not just to patients by reducing their time under anesthesia, but also improving the workflow for physicians. VIVO has the potential to allow additional procedures in the EP labs due to increased efficiency and reduce the amount of patient backlog. VIVO is showing tremendous potential to improve workflows and outcomes that help patients, physicians and hospitals."

Mr. Jenkins continued, "This publication joins a number of other publications and scientific presentations on the advantages of utilization of the VIVO technology within the hospital setting. Combined with almost 1,000 procedures performed to date with VIVO, the early experience is accelerating to what we believe will become widespread clinical acceptance and usage."

About Ra Medical Systems

Ra Medical, and its wholly owned subsidiary Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

CONTACTS:

At the Company
David Jenkins
973-691-2000
mhuck@catheterprecision.com

SOURCE: Ra Medical Systems, Inc.

View source version on accesswire.com:
https://www.accesswire.com/742477/Ra-Med-Electrophysiology-Division-Announces-New-Publication-of-Clinical-Data

FAQ

What is the significance of the new study on VIVO for RMED?

The study confirms that VIVO reduces mapping time by nearly 30%, enhancing procedure efficiency and patient safety.

How many procedures have been performed using VIVO?

Approximately 1,000 procedures have been conducted with VIVO to date.

What does the study reveal about patient outcomes with VIVO?

The research indicates that previously ineligible patients can now successfully undergo ablation using VIVO.

When was the clinical data for VIVO published?

The clinical data was published on March 8, 2023.

What is Ra Medical Systems' focus regarding VIVO?

Ra Medical Systems focuses on developing innovative medical devices to improve the treatment of cardiac arrhythmias.